Anteotech Ltd
ASX:ADO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.018
0.041
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Anteotech Ltd
Total Equity
Anteotech Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Anteotech Ltd
ASX:ADO
|
Total Equity
AU$5.3m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-3%
|
||
Proteomics International Laboratories Ltd
ASX:PIQ
|
Total Equity
AU$9.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Total Equity
AU$102.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
Cryosite Ltd
ASX:CTE
|
Total Equity
AU$1.4m
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-13%
|
||
Genetic Signatures Ltd
ASX:GSS
|
Total Equity
AU$61.1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
||
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Total Equity
AU$21.3m
|
CAGR 3-Years
28%
|
CAGR 5-Years
92%
|
CAGR 10-Years
N/A
|
Anteotech Ltd
Glance View
AnteoTech Ltd. is a global nano-technology company, which develops, manufactures, and distributes products for the life sciences, clinical diagnostics and bio-separations markets. The company is headquartered in Eight Mile Plains, Queensland. The company went IPO on 2000-04-11. The firm is focused on the development and commercialization of its intellectual property of specialized surfaces used in the life sciences, diagnostics, energy and medical devices markets. The firm's products include AnteoCoat, AnteoBind and AnteoRelease, which are used in the energy, diagnostic and medical device markets. The firm's AnteoBind is an aqueous nanosized molecular glue (polymeric metal ions) used in a single-step process to facilitate multivalent coordination to bind carbohydrate polymers, antibodies, and proteins to synthetic substrates in assay development. The firm is also developing, SARS-CoV-2 Ag rapid test, which is a single-use, disposable, lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal specimens collected from individuals who are suspected of COVID-19 infection.
See Also
What is Anteotech Ltd's Total Equity?
Total Equity
5.3m
AUD
Based on the financial report for Jun 30, 2024, Anteotech Ltd's Total Equity amounts to 5.3m AUD.
What is Anteotech Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
-3%
Over the last year, the Total Equity growth was 123%. The average annual Total Equity growth rates for Anteotech Ltd have been -37% over the past three years , 5% over the past five years , and -3% over the past ten years .